The following is the introductory presentation to the 1994 ISLAR meeting held in Boston from 16 to 19 October 1994. The Editor is again grateful to the organizer, the Zymark Corporation, for permission to publish the papers in the Managing Laboratory Automation Session read at ISLAR.

BACKGROUND In Finland, buprenorphine (Subutex) is the most abused opioid. In order to curb this problem, many treatment centres transferred ("forced transfer") their buprenorphine patients to the buprenorphine plus naloxone (Suboxone) combination product in late 2003. METHODS Data from a retrospective study involving five different treatment centers, examining the effects of switching patient...

Buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) received Food and Drug Administration approval in 2002 for the treatment of opioid dependence. Introduction of these drugs expanded the availability of opioid-dependence treatment options to reduce the morbidity and mortality associated with opioid abuse, and buprenorphine has become an increasingly prescribed component of office-bas...

after intravenous use of oral high dose Presumed ocular candidiasis in drug misusers service Email alerting the top right corner of the online article.

Buprenorphine (BUP) is a powerful semisynthetic analgesic. The molecular structure of BUP is closely related to that of morphine, yet it has been estimated to be at least 25 times more potent. Initially, it was available for the treatment of both acute and chronic pain (marketed under various trade names including; Temgesic, Buprenex and Subutex). Following administration, BUP is absorbed and m...

We consider a therapeutic market with potentially three pharmaceutical firms. Two of the firms offer horizontally differentiated brand-name drugs. One of the brand-name drugs is a new treatment under patent protection that will be introduced if the profits are sufficient to cover the entry costs. The other brand-name drug has already lost its patent and faces competition from a third firm offer...